Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PTC THERAPEUTICS, INC.PTCT · Entity 3803 | CHIEF FINANCIAL OFFICER | March 27, 2023 | March 29, 2023 |
| Replimune Group, Inc.REPL · Entity 4707 | Chief Financial Officer | August 17, 2026 | August 19, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PTC THERAPEUTICS, INC.
Report date March 27, 2023 · Filed March 29, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 38,925 |
Reported balance
After 2023-03-27 transaction · row 1
1 source rowRow 1 · 2023-03-27 · Sale · Disposed 7,363 · Balance 38,925 F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 24, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 24, 2023.
Replimune Group, Inc.
Report date August 17, 2026 · Filed August 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 215,852 |
Reported balance
After 2026-08-17 transaction · row 1
1 source rowRow 1 · 2026-08-17 · Sale · Disposed 9,256 · Balance 215,852 F1: Represents shares of the Issuer's common stock (the "Shares") sold to cover tax withholding obligations in connection with the partial vesting of the Reporting Person's Restricted Stock Units ("RSU"). The transaction reported herein was made in accordance with the irrevocable "sell to cover" provision set forth in the award agreements under which the RSUs were granted and does not represent a discretionary sale by the Reporting Person. F2: The price reported reflects a weighted average price of the Shares. The Shares were sold in multiple transactions at prices ranging from $14.20 to $14.28 per Share. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the Securities Exchange Commission staff, upon request, information regarding the number of Shares sold at each price within the range. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of the Issuer's common stock (the "Shares") sold to cover tax withholding obligations in connection with the partial vesting of the Reporting Person's Restricted Stock Units ("RSU"). The transaction reported herein was made in accordance with the irrevocable "sell to cover" provision set forth in the award agreements under which the RSUs were granted and does not represent a discretionary sale by the Reporting Person.
F2: The price reported reflects a weighted average price of the Shares. The Shares were sold in multiple transactions at prices ranging from $14.20 to $14.28 per Share. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the Securities Exchange Commission staff, upon request, information regarding the number of Shares sold at each price within the range.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 29, 2020 Filed Jan 31, 2020 21:43 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 9,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001070081-20-000052 · wf-form4_158050700018201.xml · nonDerivative · entry 1 Hill Emily Luisa · CIK 0001778279 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,191 F1 · shares: Restricted stock units granted on January 29, 2020 that vest in four equal installments over four years, commencing on January 29, 2021. Read SEC document |
| January 23, 2020 Filed Jan 27, 2020 21:14 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 330 | $53.25 | $17,571.51 |
DisclosureSEC source: 0001070081-20-000024 · wf-form4_158015963563331.xml · nonDerivative · entry 1 Hill Emily Luisa · CIK 0001778279 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,891 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 909 RSUs from a January 22, 2019 grant of 3,636 RSUs. Read SEC document |
| January 07, 2020 Filed Jan 8, 2020 23:03 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 63 | $49.62 | $3,126.12 |
DisclosureSEC source: 0001070081-20-000010 · wf-form4_157852459783596.xml · nonDerivative · entry 3 Hill Emily Luisa · CIK 0001778279 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,221 F3 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 179 RSUs from a January 4, 2016 grant of 715 RSUs. Read SEC document |
| January 06, 2020 Filed Jan 8, 2020 23:03 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 200 | $48.17 | $9,633.60 |
DisclosureSEC source: 0001070081-20-000010 · wf-form4_157852459783596.xml · nonDerivative · entry 2 Hill Emily Luisa · CIK 0001778279 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,284 F2 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 600 RSUs from a January 3, 2018 grant of 2,400 RSUs. Read SEC document |
| January 06, 2020 Filed Jan 8, 2020 23:03 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 121 | $48.17 | $5,828.33 |
DisclosureSEC source: 0001070081-20-000010 · wf-form4_157852459783596.xml · nonDerivative · entry 1 Hill Emily Luisa · CIK 0001778279 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,484 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 382 RSUs from a January 3, 2017 grant of 1,530 RSUs. Read SEC document |
| May 31, 2019 Filed Jun 3, 2019 21:39 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right To Buy) · Derivative | 50,000 | $40.10 Strike: $40.10 | $2,005,000.00 |
DisclosureSEC source: 0001070081-19-000034 · wf-form4_155959796974204.xml · derivative · entry 2 Hill Emily Luisa · CIK 0001778279 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2029-05-30 F1 · derivative.exercise_date: This option was granted on May 31, 2019 and vests over four years, with 25% of the shares underlying the option vesting on May 31, 2020, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning August 31, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.